Ian Mortimer is the President and CEO of Xenon Pharmaceuticals, a role he has held since January 2021. He has a strong background in finance and management. Before becoming CEO, he served as President and Chief Financial Officer, where he...
Ian Mortimer is the President and CEO of Xenon Pharmaceuticals, a role he has held since January 2021. He has a strong background in finance and management. Before becoming CEO, he served as President and Chief Financial Officer, where he focused on the company’s financial health and operational efficiency. His education includes an M.B.A. from Queen’s University and a B.Sc. in Microbiology from the University of British Columbia, showing a blend of business and science knowledge. Ian's experience in the biotech field includes significant time at Tekmira Pharmaceuticals, where he helped navigate the company to a successful NASDAQ listing. He is also a Chartered Professional Accountant. Among his recent achievements, he received total compensation of over $1 million in 2023, with a substantial portion tied to performance metrics tied to the company’s objectives. Ian is known for his hands-on approach and commitment to driving forward the R&D goals at Xenon, aiming to improve treatments for patients. His leadership style suggests a strategic focus on aligning company goals with shareholder interests in the competitive biotech industry.